Boston Immune Technologies & Therapeutics is a clinical-stage biotechnology company developing a novel class of antagonist antibodies targeting TNF superfamily receptors with applications in oncology, inflammation, autoimmunity, and infectious disease. Its lead program, BITR2101, is a monoclonal antibody that antagonizes TNFR2, a receptor implicated in tumor immune suppression and resistance mechanisms in the tumor microenvironment.

VISIT WEBSITE